Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis

1. Clinical evaluation of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies. 2. Construction of a combined treatment system of multimodal ablation therapy combined with immunotherapy and chemotherapy. 3. Transformation and clinical application of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies.

Trial Details

NCT ID
NCT06307080
Phase
NA
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Multi-mode thermal ablation device
  • Intravenous anti-PD-1 and chemotherapy
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • age 18-70 years old, gender is not limited;
  • Newly diagnosed pancreatic cancer with liver metastasis confirmed by pathology or consistent with clinical diagnosis, and no metastases to organs o…
  • Imaging evaluable tumors with safe access to puncture;
  • The number of half liver tumors ≤3 and the size of each tumor ≤3 cm;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →